Some of these compounds, however, are bioactive molecules with potential or current applications, particularly anti-tumoral compounds such as glionitrin A [78], and the well-known fumagillin and related compounds, with applications against amebiasis [54], microsporidiosis [55], and with known anti-angiogenic activity as inhibitors of the human type 2 methionine aminopeptidase (MetAP2) [56,57]. The gene discussed is METAP2; the disease is microsporidiosis.